Bulletin of Experimental Biology and Medicine

, Volume 164, Issue 3, pp 351–355 | Cite as

Five Hypermethylated MicroRNA Genes as Potential Markers of Ovarian Cancer

  • E. A. Braga
  • V. I. Loginov
  • A. M. Burdennyi
  • E. A. Filippova
  • I. V. Pronina
  • S. V. Kurevlev
  • T. P. Kazubskaya
  • D. N. Kushlinskii
  • D. O. Utkin
  • V. D. Ermilova
  • N. E. Kushlinskii
ONCOLOGY
  • 21 Downloads

MicroRNA and methylation are important epigenetic mechanisms in the pathogenesis of cancer. The role of a group of microRNA hypermethylated genes in the pathogenesis of ovarian cancer was studied and their diagnostic and prognostic potential was evaluated. Studies on a representative sample of 54 ovarian cancer specimens with the use of methyl-specific PCR resulted in detection of five microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) methylated in the majority of tumor specimens in comparison with paired specimens of histologically intact tissue (37-57% vs. 4-9%, p<0.01). Methylation of three genes (MIR-9-1, MIR-9-3, and MIR-130b) was significantly (p≤0.05) associated with the parameters of ovarian cancer progress (clinical stage, differentiation degree, tumor size, and presence of metastases). These findings attest to oncosuppressive role of the studied microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) in the pathogenesis and progress of ovarian cancer and indicated their prognostic potential.

Key Words

microRNA hypermethylation ovarian cancer metastases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Braga EA, Loginov VI, Pronina IV, Burdennyy AM, Kubatiev AA, Khodyrev DS, Rykov SV, Friedman MV, Kazubskaya TP, Kushlinskii NE. Upregulation of RHOA and NKIRAS1 genes in lung tumors is associated with loss of their methylation as well as with methylation of regulatory miRNA genes. Biochemistry (Moscow). 2015;80(4):483-494.CrossRefPubMedGoogle Scholar
  2. 2.
    Loginov VI, Burdennyy AM, Pronina IV, Khokonova VV, Kurevljov SV, Braga EA, Kazubskaya TP, Kushlinskii NE. Novel miRNA genes hypermethylated in breast cancer. Mol. Biol. 2016;50(5):705-709.CrossRefGoogle Scholar
  3. 3.
    Loginov VI, Braga EA, Rykov SV, Fridman MV. Methylation of miRNA genes and oncogenesis. Biochemistry (Moscow). 2015;80(2):145-162.CrossRefPubMedGoogle Scholar
  4. 4.
    Rykov SV, Khodyrev DS, Pronina IV, Loginov VI, Braga EA, Kazubskaya TP. Novel miRNA genes methylated in lung tumors. Rus. J. Genetics. 2013;49(7):782-786.CrossRefGoogle Scholar
  5. 5.
    He L, Zhang L, Wang M, Wang W. miR-9 functions as a tumor inhibitor of cell proliferation in epithelial ovarian cancer through targeting the SDF-1/CXCR4 pathway. Exp. Ther. Med. 2017;13(4):1203-1208.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kinose Y, Sawada K, Nakamura K, Kimura T. The role of microRNAs in ovarian cancer. Biomed. Res. Int. 2014;2014. ID 249393. doi:  https://doi.org/10.1155/2014/249393.CrossRefGoogle Scholar
  7. 7.
    Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA. Epigenetic regulation of microRNAs in cancer: An integrated review of literature. Mutat. Res. 2011;717(1-2):77-84.CrossRefPubMedGoogle Scholar
  8. 8.
    Li X, Pan Q, Wan X, Mao Y, Lu W, Xie X, Cheng X. Methylation-associated Has-miR-9 deregulation in paclitaxel-resistant epithelial ovarian carcinoma. BMC Cancer. 2015;15:509. doi:  https://doi.org/10.1186/s12885-015-1509-1.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Loginov VI, Dmitriev AA, Senchenko VN, Pronina IV, Khodyrev DS, Kudryavtseva AV, Krasnov GS, Gerashchenko GV, Chashchina LI, Kazubskaya TP, Kondratieva TT, Lerman MI, Angeloni D, Braga EA, Kashuba VI. Tumor suppressor function of the SEMA3B gene in human lung and renal cancers. PLoS One. 2015;10(5):e0123369. doi: https://doi.org/10.1371/journal. pone.0123369.Google Scholar
  10. 10.
    Pal MK, Jaiswar SP, Dwivedi VN, Tripathi AK, Dwivedi A, Sankhwar P. MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer. Cancer Biol. Med. 2015;12(4):328-341.Google Scholar
  11. 11.
    Paudel D, Zhou W, Ouyang Y, Dong S, Huang Q, Giri R, Wang J, Tong X. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer. Gene. 2016;586(1):48-55.CrossRefPubMedGoogle Scholar
  12. 12.
    Torres-Ferreira J, Ramalho-Carvalho J, Gomez A, Menezes FD, Freitas R, Oliveira J, Antunes L, Bento MJ, Esteller M, Henrique R, Jerónimo C. MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors. Mol. Cancer. 2017;16(1):26. doi:  https://doi.org/10.1186/s12943-017-0604-0.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    WHO Classification of Tumours of Female Reproductive Organs. Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. Lyon, 2014.Google Scholar
  14. 14.
    Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L, Wang Z. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colonystimulating factor 1. Gynecol. Oncol. 2012;124(2):325-334.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhou B, Xu H, Xia M, Sun C, Li N, Guo E, Guo L, Shan W, Lu H, Wu Y, Li Y, Yang D, Weng D, Meng L, Hu J, Ma D, Chen G, Li K. Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer. Front. Med. 2017;11(2):214-222.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • E. A. Braga
    • 1
    • 2
  • V. I. Loginov
    • 1
    • 2
  • A. M. Burdennyi
    • 1
  • E. A. Filippova
    • 1
  • I. V. Pronina
    • 1
  • S. V. Kurevlev
    • 1
  • T. P. Kazubskaya
    • 3
  • D. N. Kushlinskii
    • 3
  • D. O. Utkin
    • 3
  • V. D. Ermilova
    • 3
  • N. E. Kushlinskii
    • 3
  1. 1.Research Institute of Pathology and PathophysiologyMoscowRussia
  2. 2.Research Centre of Medical GeneticsMoscowRussia
  3. 3.N. N. Blokhin Russian Cancer Research Centerthe Ministry of Health of the Russian FederationMoscowRussia

Personalised recommendations